肿瘤微环境在三阴性乳腺癌免疫治疗中的研究进展

doi:10.3969/j.issn.1006-7795.2023.05.026

摘要/Abstract

摘要： 三阴性乳腺癌（triple negative breast cancer，TNBC）具有高侵袭性、高转移率、高复发转移风险等特点，目前仍缺乏有效分子治疗靶点，晚期患者中位生存时间仅为1年，是预后最差的一类乳腺癌亚型。研究发现肿瘤微环境（tumor microenvironment，TME）中存在着多种肿瘤相关免疫细胞及基质细胞，其在TNBC的发生发展、侵袭转移过程中起着关键作用，目前越来越多的研究聚焦于免疫治疗在TNBC治疗中的价值。TME中存在大量潜在免疫治疗靶点，通过对TME的深入研究，或许能为TNBC的免疫治疗提供新思路。本文对TNBC的TME成分及其相关靶向治疗最新进展进行综述。

关键词: 三阴性乳腺癌, , 肿瘤微环境, , 免疫治疗, , 肿瘤浸润淋巴细胞, 免疫检查点

Abstract: Triple negative breast cancer (TNBC) is associated with high invasiveness, high metastasis，high risk of recurrence and metastasis. Currently, there is still a lack of effective molecular therapeutic targets, and the median survival time for patients with advanced disease is only 1 year, which is the worst prognosis for a subtype of breast cancer. It has been identified that there are a variety of tumor-associated immune cells and stromal cells in the tumor microenvironment（TME）, which play a key role in the development, invasion and metastasis of TNBC, now an increasing numbers of studies are focusing on the value of immunotherapy in TNBC. TME hosts many potential targets for immunotherapy, and the thorough exploration of TME may provide new perspectives for immunotherapy in TNBC. This study provides a comprehensive review of the latest advances in understanding the components of the TME in TNBC，and their associated targeted therapeutic strategies.

Key words: triple negative breast cancer, tumor microenvironment, immunotherapy, , tumor-infiltrating lymphocytes, immune checkpoint

中图分类号:

R737.9

徐晶星, 周全, 应建明. 肿瘤微环境在三阴性乳腺癌免疫治疗中的研究进展[J]. 首都医科大学学报, 2023, 44(5): 882-888.

Xu Jingxing, Zhou Quan, Ying Jianming. Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer[J]. Journal of Capital Medical University, 2023, 44(5): 882-888.

参考文献

［1］Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022［J］. CA Cancer J Clin, 2022, 72(1): 7-33.
［2］Sakach E, O'Regan R, Meisel J, et al. Molecular classification of triple negative breast cancer and the emergence of targeted therapies［J］. Clin Breast Cancer, 2021, 21(6): 509-520.
［3］Nelson M A, Ngamcherdtrakul W, Luoh S W, et al. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer［J］. Cancer Metastasis Rev, 2021, 40(2): 519-536.
［4］Denkert C, Von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy［J］. Lancet Oncol, 2018, 19(1): 40-50.
［5］Luen S J, Salgado R, Dieci M V, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy［J］. Ann Oncol, 2019, 30(2): 236-242.
［6］丁耘峰, 黄惠莲, 徐炜, 等. 三阴性乳腺癌组织中PD-1/PD-L1轴表达与TILs关系及临床病意义［J］. 临床肿瘤学杂志, 2021, 26(2): 140-145.
［7］Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers［J］. J Clin Oncol, 2019, 37(7): 559-569.
［8］Dieci M V, Tsvetkova V, Griguolo G, et al. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: analysis of 244 stage Ⅰ-Ⅲ patients treated with standard therapy［J］. Eur J Cancer, 2020, 136: 7-15.
［9］钟恋君, 王进京, 郑洪. 三阴型乳腺癌间质肿瘤浸润淋巴细胞CD4、CD8、Foxp3和PD-L1表达的临床病理意义［J］. 临床与实验病理学杂志, 2022, 38(3): 278-283, 288.
［10］Goda N, Nakashima C, Nagamine I, et al. The effect of intratumoral interrelation among FOXP3+ regulatory T cells on treatment response and survival in triple-negative breast cancer［J］. Cancers (Basel), 2022, 14(9): 2138.
［11］Yao S, Zhu Y W, Chen L P. Advances in targeting cell surface signalling molecules for immune modulation［J］. Nat Rev Drug Discov, 2013, 12(2): 130-146.
［12］Quintana Á, Peg V, Prat A, et al. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer［J］. Eur J Cancer, 2021, 148: 134-145.
［13］Liu J N, Kong X S, Huang T, et al. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study［J］. Front Immunol, 2020, 11: 2048.
［14］Vardas V, Tolios A, Christopoulou A, et al. Immune checkpoint and EMT-related molecules in circulating tumor cells (CTCs) from triple negative breast cancer patients and their clinical impact［J］. Cancers (Basel), 2023, 15(7): 1974.
［15］Quezada S A, Peggs K S. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer［J］. Br J Cancer, 2013, 108(8): 1560-1565.
［16］Hoda R S, Brogi E, Dos Anjos C H, et al. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma［J］. Mod Pathol, 2020, 33(11): 2221-2232.
［17］Sun X J, Zhai J, Sun B H, et al. Effector memory cytotoxic CD3⁺/CD8⁺/CD45RO⁺ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer［J］. Mod Pathol, 2022, 35(5): 601-608.
［18］刘鲁宁, 陈雪梅, 马恩奇, 等. 人CD137抗体促进NK细胞对乳腺癌细胞特异性杀伤作用的体外研究［J］. 中华细胞与干细胞杂志: 电子版, 2020, 10(6): 346-353.
［19］Jin H, Choi H, Kim E S, et al. Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase-type plasminogen activator［J］. Oncol Rep, 2021, 45(1): 299-308.
［20］Milling L E, Garafola D, Agarwal Y, et al. Neoadjuvant sting activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation［J］. Cancer Immunol Res, 2022, 10(1): 26-39.
［21］Ding S N, Qiao N, Zhu Q C, et al. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer［J］. Cancer Commun (Lond), 2023, 43(6): 661-684.
［22］Yang M, Ma B, Shao H S, et al. Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells［J］. BMC Cancer, 2016, 16: 419.
［23］Noy R, Pollard J W. Tumor-associated macrophages: from mechanisms to therapy［J］. Immunity, 2014, 41(1): 49-61.
［24］Steenbrugge J, Breyne K, Demeyere K, et al. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer［J］. J Exp Clin Cancer Res, 2018, 37(1): 191.
［25］Yuan Z Y, Luo R Z, Peng R J, et al. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis［J］. Onco Targets Ther, 2014, 7: 1475-1480.
［26］Jamiyan T, Kuroda H, Yamaguchi R, et al. CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast［J］. Virchows Arch, 2020, 477(6): 767-775.
［27］Bao X W, Shi R, Zhao T Y, et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC［J］. Cancer Immunol Immunother, 2021, 70(1): 189-202.
［28］Fridlender Z G, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN［J］. Cancer Cell, 2009, 16(3): 183-194.
［29］Wei B J, Yao M Y, Xing C Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis［J］. Onco Targets Ther, 2016, 9: 5567-5575.
［30］Gao S M, Tang W J, Zuo B L, et al. The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy［J］. Front Oncol, 2022, 12: 1065606.
［31］Schott A F, Goldstein L J, Cristofanilli M, et al. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer［J］. Clin Cancer Res, 2017, 23(18): 5358-5365.
［32］Li K D, Liu T, Chen J, et al. Survivin in breast cancer-derived exosomes activates fibroblasts by up-regulating SOD1, whose feedback promotes cancer proliferation and metastasis［J］. J Biol Chem, 2020, 295(40): 13737-13752.
［33］Liubomirski Y, Lerrer S, Meshel T, et al. Notch-mediated tumor-stroma-inflammation networks promote invasive properties and CXCL8 expression in triple-negative breast cancer［J］. Front Immunol, 2019, 10: 804.
［34］Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer［J］. Cancer Cell, 2018, 33(3): 463-479.e10.
［35］Alcaraz L B, Mallavialle A, Mollevi C, et al. SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity［J］. Int J Cancer, 2023, 152(6): 1243-1258.
［36］Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion［J］. Cancer Res, 2011, 71(7): 2455-2465.
［37］Zhao C R, Wu M, Zeng N, et al. Cancer-associated adipocytes: emerging supporters in breast cancer［J］. J Exp Clin Cancer Res, 2020, 39(1): 156.
［38］Zhang C Y, Yue C Y, Herrmann A, et al. STAT3 Activation-induced fatty acid oxidation in CD8⁺ T effector cells is critical for obesity-promoted breast tumor growth［J］. Cell Metab, 2020, 31(1): 148-161.e5.
［39］Liu Q, Dong H T, Zhao T T, et al. Cancer-associated adipocytes release FUCA2 to promote aggressiveness in TNBC［J］. Endocr Relat Cancer, 2022, 29(3): 139-149.
［40］Alshetaiwi H, Pervolarakis N, McIntyre L L, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics［J］. Sci Immunol, 2020, 5(44): eaay6017.
［41］Kumar V, Donthireddy L, Marvel D, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors［J］. Cancer Cell, 2017, 32(5): 654-668.e5.
［42］Vito A, Salem O, El-Sayes N, et al. Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells［J］. Commun Biol, 2021, 4(1): 859.
［43］Pickup M W, Mouw J K, Weaver V M. The extracellular matrix modulates the hallmarks of cancer［J］. EMBO Rep, 2014, 15(12): 1243-1253.
［44］Hayashi M, Yamamoto Y, Ibusuki M, et al. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer［J］. Ann Surg Oncol, 2012, 19(9): 3042-3049.
［45］Turunen S P, Tatti-Bugaeva O, Lehti K. Membrane-type matrix metalloproteases as diverse effectors of cancer progression［J］. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt A): 1974-1988.

[1]	杨一凡, 王雅梅. 凋亡诱导因子2在乳腺癌中的表达及其相关作用[J]. 首都医科大学学报, 2023, 44(2): 248-257.
[2]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[3]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[4]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[7]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[8]	陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.
[9]	徐泉, 刘玉洁, 潘钰, 郑秀瑗, 刘静民, 孙小花, 邹丽丽, 马丽娜, 严红松. 生物电阻抗测试频率对乳腺癌相关淋巴水肿定量评估的影响[J]. 首都医科大学学报, 2018, 39(5): 747-751.
[10]	彭楠, 刘慧敏, 王伟新, 刘明, 王志群. 乳腺浸润性导管癌磁共振弥散及动态增强多参数定量分析研究[J]. 首都医科大学学报, 2018, 39(2): 190-194.
[11]	王利娟, 杨春, 谷牧青, Pierre Hardy, 阮祥燕, Alfred O. Mueck. 受孕激素调节的microRNAs与乳腺癌的关系[J]. 首都医科大学学报, 2017, 38(4): 521-525.
[12]	谷牧青, 杨春, 王利娟, Pierre Hardy, 贾婵维, 阮祥燕. miR-181a与乳腺癌关系的研究进展[J]. 首都医科大学学报, 2017, 38(4): 526-529.
[13]	骆成玉. 乳腺癌治疗从标准到精准微创[J]. 首都医科大学学报, 2016, 37(3): 331-335.
[14]	王子函, 滕长胜, 葛智成, 张慧明, 苑著, 高银光, 张忠涛, 屈翔. 单孔法全腔镜局部扩大切除术进行保乳手术的临床应用[J]. 首都医科大学学报, 2016, 37(3): 336-340.
[15]	崔智淼, 骆成玉, 李鑫, 刘宝胤, 丁毅. 乳腔镜辅助保留NAC乳腺癌改良根治术并假体植入Ⅰ期成形的临床研究[J]. 首都医科大学学报, 2016, 37(3): 341-345.